DigitalBridge to Participate in Upcoming Investor and Industry Conferences in June 2025
BOCA RATON, Fla., June 02, 2025--(BUSINESS WIRE)--DigitalBridge Group, Inc. ("DigitalBridge" or the "Company") (NYSE: DBRG), a leading global alternative asset manager dedicated to investing in digital infrastructure, today announced senior executives from DigitalBridge will participate in the following upcoming investor and industry events:
June 2-5: 2025 Alaska Sustainable Energy Conference – Anchorage, Alaska
Severin White, Managing Director at DigitalBridge, will be present "The Intersection of Data and Demand" on Wednesday, June 4, 2025, at 9:25 am AKDT.
June 3-5: Datacloud Global Congress – Cannes, France
Manjari Govada, Managing Director at DigitalBridge, will participate in the panel "Risk Across the Data Centre Lifecycle" on Wednesday, June 4, 2025 at 10:50 am CEST.
Senior management from the firm will be conducting 1x1 meetings at the conference.
June 10-11: Morgan Stanley US Financials Conference – New York
Marc Ganzi, Chief Executive Officer at DigitalBridge, will deliver a fireside chat on Wednesday, June 11, 2025, at 3:15 pm EDT.
Senior management from the firm will be conducting 1x1 meetings with investors at the conference.
About DigitalBridge
DigitalBridge (NYSE: DBRG) is a leading global alternative asset manager dedicated to investing in digital infrastructure. With a heritage of 30 years investing in and operating businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, the DigitalBridge team manages approximately $100 billion of infrastructure assets on behalf of its limited partners and shareholders. For more information, visit: www.digitalbridge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602500109/en/
Contacts
Investors:Severin WhiteManaging Director(212) 547-2777severin.white@digitalbridge.com Media:Joele Frank, Wilkinson Brimmer KatcherJon Keehner / Sarah Salky(212) 355-4449dbrg-jf@joelefrank.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
27 minutes ago
- Yahoo
Sprinklr (CXM) Stock Trades Up, Here Is Why
Shares of customer experience software provider Sprinklr (NYSE:CXM) jumped 5.7% in the morning session after the company reported a "beat-and-raise" quarter (Q1 FY-26). Sprinklr raised its full-year revenue and EPS guidance, which blew past analysts' expectations. The quarter was also solid as its revenue, EPS, and adjusted operating income exceeded Wall Street's estimates. The big win came on margins. Operating margin on a non-GAAP basis climbed to 18% from 11% last year, helped by pulling back on sales and marketing costs. That made a real difference in earnings per share, which jumped more than 30% and blew past Wall Street's estimates. Overall, we think this was a solid "beat-and-raise" quarter. After the initial pop the shares cooled down to $8.75, up 2.2% from previous close. Is now the time to buy Sprinklr? Access our full analysis report here, it's free. Sprinklr's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 12 months ago when the stock dropped 24.2% on the news that the company reported weak first quarter results and provided full-year revenue guidance below expectations after being lowered. Also, its revenue guidance for next quarter missed Wall Street's estimates. The company called out a soft demand environment with longer sales cycles and heightened budgetary scrutiny. In addition, it observed higher churn in its core product suites due to reduced marketing spend, elimination of programs, and seat reductions. These issues contributed to the weak guidance as management expects the elevated churn level to continue for the full year FY '25. On the other hand, Sprinklr recorded significant improvement in new large contract wins. Overall, the guidance was quite bad and weighed on the stock. Following the results, D.A. Davidson downgraded the stock's rating from Buy to Neutral, while Cantor Fitzgerald also lowered the rating from Overweight to Neutral. Sprinklr is up 2.4% since the beginning of the year, but at $8.75 per share, it is still trading 19.3% below its 52-week high of $10.84 from June 2024. Investors who bought $1,000 worth of Sprinklr's shares at the IPO in June 2021 would now be looking at an investment worth $496.87. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
34 minutes ago
- Yahoo
Industrias Unidas, S.A. de C.V. Consolidated Results of Operations for Q1 2025
MEXICO CITY, June 04, 2025--(BUSINESS WIRE)--Industrias Unidas, S.A. de C.V. ("IUSA" or the "Company") has announced its unaudited results for the three months ended March 31 of 2025. Figures are unaudited and have been prepared in accordance with Mexican Financial Reporting Standards ("MFRS"), which are different in certain respects from Generally Accepted Accounting Principles in the United States ("U.S. GAAP"). The results from any interim period are not necessarily indicative of the results that may be expected for a full fiscal year. Unless stated otherwise, reference herein to "Pesos", "pesos", or "Ps." are to pesos, the legal currency of Mexico and references to "U.S. dollars", "dollars", "U.S. $" or "$" are to United States dollars, the legal currency of the United States of America. Except as otherwise indicated, all peso amounts are presented herein in pesos with purchasing power as of March 31, 2025, and in pesos with their historical value for other dates cited. The dollar translations provided in this document are calculated solely for the convenience of the reader using an exchange rate of Ps. 20.46 per U.S. dollar, the exchange rate published by Banco de Mexico, the country's central bank, on March 31, 2025. Three months ended March 31, 2025, compared to three months ended March 31, 2024. The following table summarizes our results of operations for the three months ending March 31, 2025, and 2024: (Figures in Millions of Pesos) For the year ended March31, 2024 2025 Revenues 6,236.3 8,876.0 Cost of Sales 4,803.3 6,922.3 Gross Profit 1,433.0 1,953.7 Selling and Administrative Expenses 630.8 805.4 Operating Income (Loss) 802.2 1,148.3 Other Expenses - Net 51.2 21.8 Comprehensive Financing Result 63.8 34.9 Taxes and Statutory Employee Profit Sharing 180.9 290.4 Equity in Income (Loss) of Associated Companies (16.0) (2.8) Consolidated Net Income (Loss) 720.3 911.8 D&A 71.5 82.2 EBITDA 1/ 873.7 1,230.5 1/ EBITDA for any period is defined as consolidated net income (loss) excluding i) depreciation and amortization, ii) total net comprehensive financing result (which is comprised of net interest expense, exchange gain or loss, monetary position gain or loss and other Financing costs), iii) other expenses net, iv) income tax and statutory employee profit sharing and v) equity in income (loss) of associated companies. EBITDA should not be considered as an alternate measure of net income or operating income, as determined on a consolidated basis using amounts derived from statements of operations prepared in accordance with MFRS, or as an indicator of operating performance or to cash flows from operating activity as a measure of liquidity. EBITDA is not a recognized term under MFRS or U.S. GAAP and does not purport to be an alternative to net income as a measure of operating performance or to cash flows from operating activity as a measure of liquidity. Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.6 million), compared to a net income of Ps.720.3 million in the same period of 2024. This represented a 26.6% increase, quarter over quarter (Q/Q). This change is primarily due to an increase in sales and hence Gross Profit. Revenues Our net revenues for the three months of 2025 increased 42.3% to Ps.8,876.0 million (U.S.$433.82 million) from Ps.6,236.3 million in the same period of 2024. This increase was driven in part by higher copper prices, combined with an increase in volume of sales. Our costs and revenues follow copper prices very closely since the market practice is to pass on to the buyer changes in raw material prices. Our sales are primarily for customers engaged in commercial, industrial and residential construction, and their related maintenance and renovation activities. We also sell to customers engaged in electrical power generation, transmission and distribution and to the sectors of gas, water and air conduction in Heating, Ventilation, Air conditioning and Refrigeration (HVACR). Our revenues consist mainly of sales of copper-based products (tubing, wire, cable and alloys) and electrical products. By country of production, approximately 61.3% of our revenues in the three months ended March 31, 2025, came from products manufactured in Mexico and the remaining 38.7% from products manufactured in the U.S. In terms of sales by region during the three months ended March 31, 2025, we derived approximately 44.0% of our revenues from sales to customers in the United States, 51.7% from customers in Mexico and 4.3% from the rest of the world ("ROW"). Cost of sales Our cost of sales in the three months ended March 31, 2025, increased by 44.1% to Ps.6,922.3 million (U.S.$338.3 million) from Ps.4,803.3 million in the same period of 2024. As a percentage of revenues, the cost of sales was 78.0% and 77.0% respectively. We reduce our cost base through several initiatives, including plant scheduling, raw material handling, and overall manufacturing overhead costs. According to our accounting policies, we make an inventory valuation at an average purchase price. In the case of copper cathodes, an aftermath adjustment is required due to the quotation period agreed with the suppliers (M+1). This initiative allows us to hedge purchases for 30 days at no additional cost. The adjustment is recorded to the cost of sales in the month in which it occurs. Gross Profit Our gross profit in the three months ended March 31, 2025, increased 36.3% to Ps.1,953.7 million (U.S.$95.5 million) from Ps.1,433.0 million in the same period of 2024. As a percentage of sales, gross profit in 2025 was 22.0% vs 23.0% in 2024. Selling and Administrative Expenses Our sales and administrative expenses in the three months ended March 31, 2025, increased 27.7% to Ps.805.4 million from Ps.630.8 in the same period of 2024. Operating Income Our operating income in the three months ended March 31, 2025, increased 43.1% to Ps. 1,148.3 million (U.S.$56.12 million) from an operating income of Ps. 802.2 in the same period of 2024. EBITDA In the three months ended March 31, 2025, our EBITDA increased 40.8% to Ps.1,230.5 million (or U.S.$60.1million), from Ps.873.7 million in the same period of 2024. The corresponding depreciation and amortization figures are Ps.422.3 million for January to March 2025 and Ps.337.7 million for the same period of 2024. Comprehensive Financing Result The following table shows our comprehensive financing results for the three months ending March 31, 2025, and 2024: (Figures in Millions of Pesos) For the year ended March 31, 2024 2025 Interest Expense (69.4) (78.5) Interest Income 51.3 30.6 Exchange Gain (Loss) - Net 88.7 88.9 Other Financing Costs (6.8) (6.1) Comprehensive Financing Result 63.8 34.9 Our comprehensive financing result in the three months ending March 31, 2025, was an expense of Ps.34.9 million, compared to an expense of Ps.63.8 million in the same period of 2024. Taxes and Statutory Employee Profit Sharing The provision for current and deferred income taxes and statutory employee profit sharing in the three months ended March 31, 2025, was an expense of Ps.290.4 million compared to an expense of Ps.180.9 million in the same period of 2024. Consolidated Net Income Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.5 million), compared to a net income of Ps.720.3 million in the same period of 2024. Liquidity and Capital Resources Liquidity As of March 31, 2025, we had cash and cash equivalents for Ps.6,436.8 million (U.S.$314.6 million). Our policy is to invest available cash in short-term instruments issued by Mexican and U.S. banks as well as in securities issued by the governments of Mexico and the U.S. Our cash flow from operations and operating margins are significantly influenced by world market prices for raw copper, as quoted by COMEX and the London Metal Exchange ("LME"). Copper prices are subject to significant market fluctuations; average copper prices increased 18.4% in the three months ending March 31, 2025, to $4.57 US dollars per pound from $3.86 US dollar per pound in the same period of 2024. We obtain short-term financing from various sources, including Mexican and international banks. Short-term financing consists in part of lines of credit denominated in pesos and dollars. As of March 31, 2025, our outstanding short-term debt, including the current portion of long-term debt totaled Ps.422.2 million (U.S.$20.6 million), all of which was dollar denominated. On the same date, our outstanding consolidated long-term debt, excluding current portion thereof, totaled Ps.4,129.0 million (U.S.$201.8 million), all of which was dollar denominated. Accounts receivable from third parties as of March 31, 2025, were Ps.6,205.1 million (U.S.$303.3 million). Days outstanding in the domestic market were 31 days as of March 31, 2025. Debt Obligations The following table summarizes our debt as of March 31, 2025: Consolidated debt March 31, 2025 (In Millions of Pesos) U.S. subsidiaries debt 35.9 Mexican debt 4,515.4 Total 4,551.3 This total includes the restructured debt of the Company. Capital Expenditures For the three months ended March 31, 2025, we invested Ps.79.1 million (U.S. $3.9 million) in capital expenditure projects, mainly related to expansion of production and maintenance. In the three months ending March 31, 2025, our capital expenditures were allocated by segments as follows: 1.0% to copper tubing, 35.0% to wire and cable, 45.0% to valves and controls, 8.0% to electrical products and the remaining and 11.0% to other divisions. By geographic region 69.0% of total capital expenditures were invested in our Mexican facilities and the remaining 31.0% in the U.S. You should read this document in conjunction with the unaudited consolidated financial statements as of March 31, 2025, including the notes to those statements. View source version on Contacts Francisco Rodriguez, frodriguez@ tel. 5255 5216 4028
